Lexaria Bioscience Corp (LEXX) Q3 2024 Earnings Report

Lexaria Bioscience Corp (LEXX) reported QQ3 2024 with a materially modest revenue base of $84,000 against a heavy operating expense burden, resulting in an EBITDA of -$1.727 million and a net loss of -$1.781 million. Revenue declined YoY by 9.82% and QoQ by 42.07%, while gross profit remained structurally flat at $84,000 (gross margin effectively 100% on reported revenue). The quarter underscored a continued burn driven by R&D and G&A expenditures (R&D $573k; G&A $1.254M) in a pre-commercial phase where Lexaria is financing IP development and platform validation rather than selling finished products. Cash burn remained meaningful at operating cash flow of -$1.267 million and free cash flow of -$1.289 million, but the company completed a financing activity that added approximately $5.043 million through common stock issuances, yielding a robust cash position of $8.46 million at period-end. The balance sheet shows a conservative debt profile, a healthy cash-to-debt posture, and an evolving equity base, which provides runway to pursue licensing and partnering opportunities tied to the DehydraTECH platform.